Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, today announced that the United States Patent and Trademark Office ...
BioWorld

Riding the Wave, exon skipper sails toward DMD filing

Wave Life Sciences Ltd. plans to file with the U.S. FDA for accelerated approval of WVE-N531, an exon skipping oligonucleotide for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon ...
The American Journal of Managed Care

WVE-N531 Shows Promising Efficacy in DMD at Interim FORWARD-53 Analysis

In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
Healio

Novel Duchenne therapy shows promise for halting disease progression

Please provide your email address to receive an email when new articles are posted on . A next-generation exon skipping therapy led to significant dystrophin ...
Seeking Alpha

Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase ...

SAN DIEGO, March 17, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...